Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
Launched by UNIVERSITY HOSPITAL, TOURS · Nov 14, 2012
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Nulliparous (no previous pregnancy ≥ 22 SA)
- • Singleton pregnancy
- • Gestational age ≤ 15 +6 weeks
- • Bilateral uterine artery notch (grade ≥ 2) and/or bilateral uterine artery PI ≥ 1.7 during first trimester ultrasound (CRL between 45 and 84 mm)
- • Maternal informed consent obtained
- • Affiliated to social security system
- Exclusion Criteria:
- • Women considering voluntary pregnancy termination (≤ 14 weeks)
- • Pre-existing (maternal) indication for premature delivery before 37 weeks
- • Fetal condition detected during the first trimester scan (fetal malformation or nuchal translucency ≥ 95th percentile)
- • Women under anticoagulation
- • Allergy or hypersensitivity to Kardegic® or one of its constituents
- • Secondary hemostasis disorder responsible for bleeding or risk of bleeding
- • Peptic ulcer under evolution
- • Lupus or antiphospholipid syndrome
About University Hospital, Tours
The University Hospital of Tours, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative clinical research and patient-centered care. With a strong emphasis on collaboration between researchers, clinicians, and community partners, the hospital fosters a dynamic environment for conducting high-quality clinical trials across various medical disciplines. Its commitment to excellence in patient safety, ethical standards, and scientific integrity positions the University Hospital of Tours as a pivotal contributor to the development of new therapies and health solutions, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Bron, , France
Caen, , France
Clermont Ferrand, , France
Grenoble, , France
La Chaussée St Victor, , France
Le Mans, , France
Lille, , France
Montpellier, , France
Nantes, , France
Nantes, , France
Nîmes, , France
Orléans, , France
Paris, , France
Toulouse, , France
Tours, , France
Fort De France, , Martinique
Patients applied
Trial Officials
Franck PERROTIN, MD-PhD
Principal Investigator
University Hospital, Tours
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials